Table 1.
Estimation of inhibitory concentration 50% (IC50) based on WST-1 viability assay following treatment with the CDK4/6 inhibitor (PD-0332991), with the PARP inhibitor (BMN-673) and with the WEE1 inhibitor MK-1775 at 24, 48 and 72 h after treatment.
| IC50 (µM) b | ||||
|---|---|---|---|---|
| Drugs | Cell Lines | 24 h | 48 h | 72 h |
| CDK4/6 (PD-0332991) |
CU-OP-2 | 25.1 | 26.8 | 35.9 |
| CU-OP-3 | 13.4 | 15.2 | 12.3 | |
| CU-OP-20 | 10.4 | 9.8 | 10.1 | |
| CU-OP-17 | 21.0 | 16.6 | 14.4 | |
| PARP (BMN-673) |
CU-OP-2 | 291.4 a | 127.2 a | 14.9 |
| CU-OP-3 | 3219 a | 81.4 a | 13.9 | |
| CU-OP-20 | 229.5 a | 30.9 | 6.0 | |
| CU-OP-17 | 93.8 a | 12.8 | 4.8 | |
| WEE1 (MK-1775) |
CU-OP-2 | 3.4 | 2.4 | 1.7 |
| CU-OP-3 | 9.6 | 0.6 | 0.2 | |
| CU-OP-20 | 2.9 | 0.4 | 0.2 | |
| CU-OP-17 | 6.5 | 0.4 | 0.2 | |
The inhibitory concentration 50% (IC50) for each cell line for each drug was determined from log concentrations effect curves in GraphPad Prism using non-linear regression analysis. a Extrapolated IC50 value, i.e., outside the tested concentration range. b IC50 values for BYL and JNJ previously calculated and presented (34).